Zentalis Pharmaceuticals ...
(ZNTL)
undefined
undefined%
At close: undefined
3.06
-2.24%
After-hours Jan 06, 2025, 07:24 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -292.19M | -237.11M | -166.09M | -118.55M | -46.38M | -23.43M |
| Depreciation & Amortization | 1.39M | 1.43M | 544.00K | 160.00K | 111.00K | 51.00K |
| Stock-Based Compensation | 54.82M | 46.84M | 35.74M | 23.15M | 617.00K | 308.00K |
| Other Working Capital | -5.05M | -2.27M | 1.35M | -667.00K | 115.00K | -40.00K |
| Other Non-Cash Items | 23.15M | 12.61M | -38.38M | 556.00K | -7.78M | -2.37M |
| Deferred Income Tax | -853.00K | -769.00K | -2.46M | 17.00K | 7.78M | 2.37M |
| Change in Working Capital | 5.86M | 13.25M | 16.56M | 7.84M | 6.51M | -1.18M |
| Operating Cash Flow | -207.82M | -163.75M | -154.09M | -86.83M | -39.14M | -24.25M |
| Capital Expenditures | -583.00K | -2.55M | -6.11M | -758.00K | -352.00K | -227.00K |
| Acquisitions | n/a | 111.63K | -14.32M | 18.42M | n/a | n/a |
| Purchase of Investments | -549.18M | -533.16M | -363.51M | -400.98M | n/a | n/a |
| Sales Maturities Of Investments | 505.31M | 421.53M | 365.82M | 116.91M | n/a | n/a |
| Other Investing Acitivies | n/a | -111.63K | -12.01K | -18.42M | n/a | n/a |
| Investing Cash Flow | -44.46M | -114.18M | -18.11M | -284.83M | -352.00K | -227.00K |
| Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | n/a | n/a | -1.15M | 32.65M | 81.83M | 9.46M |
| Financial Cash Flow | 237.30M | 261.04M | 178.52M | 360.44M | 81.83M | 9.47M |
| Net Cash Flow | -14.98M | -16.89M | 6.31M | -11.22M | 42.34M | -15.01M |
| Free Cash Flow | -208.41M | -166.30M | -160.20M | -87.58M | -39.49M | -24.48M |